MiRNAs as potential molecular targets in heart failure

Future Cardiology

Volumn 10, Issue 6, 2014, Pages 789-800

  Katz, Michael G ^a   Fargnoli, Anthony S ^a   Williams, Richard D ^a   Kendle, Andrew P ^a   Steuerwald, Nury M ^a   Bridges, Charles R ^a  

^a LEVINE CANCER INSTITUTE   (United States)

Author keywords

apoptosis; cardiac remodeling; fibrosis; heart failure; microRNAs; myocardial hypertrophy

Indexed keywords

MICRORNA;

APOPTOSIS; FIBROSIS; GENE CONTROL; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; MUSCLE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; PATHOLOGY; PHYSIOLOGY;

HEART FAILURE; HUMANS; MICRORNAS; VENTRICULAR REMODELING;

EID: 84919787293     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.14.64     Document Type: Review

References (61)

1. Chamberlain AM, Manemann SM, Dunlay SM et al. Self-rated health predicts healthcare utilization in heart failure. J. Am. Heart Assoc. 3(3), e000931 (2014).
2. Roger VL, Weston SA, Redfield MM et al. Trends in heart failure incidence and survival in a community-based population. JAMA 292(3), 344-350 (2004).
3. Thum T, Galuppo P, Wolf C et al. MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 116(3), 258-267 (2007).
4. Kartha RV, Subramanian S. MicroRNAs in cardiovascular diseases: Biology and potential clinical applications. J. Cardiovasc. Transl. Res. 3(3), 256-270 (2010).
5. Divakaran V, Mann DL. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ. Res. 103(10), 1072-1083 (2008).
6. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5), 843-854 (1993).
7. Ambros V, Lee RC, Lavanway A et al. MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr. Biol. 13(10), 807-818 (2003).
8. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: Opportunities and obstacles. Nat. Rev. Drug Discov. 11(11), 860-872 (2012).
9. Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease. J. Cardiovasc. Transl. Res. 3(3), 251-255 (2010).
10. Catalucci D, Gallo P, Condorelli G. MicroRNAs in cardiovascular biology and heart disease. Circ. Cardiovasc. Genet. 2(4), 402-408 (2009).
11. Altuvia Y, Landgraf P, Lithwick G et al. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res. 33(8), 2697-2706 (2005).
12. Berezikov E, Guryev V, van de Belt J et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 120(1), 21-24 (2005).
13. Xu C, Lu Y, Pan Z et al. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J. Cell Sci. 120(Pt 17), 3045-3052 (2007).
14. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 136(2), 215-233 (2009).
15. Barringhaus KG, Zamore PD. MicroRNAs: Regulating a change of heart. Circulation 119(16), 2217-2224 (2009).
16. Cordes KR, Srivastava D. MicroRNA regulation of cardiovascular development. Circ. Res. 104(6), 724-732 (2009).
17. Eulalio A, Mano M, Dal Ferro M et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 492(7429), 376-381 (2012).
18. Latronico MV, Condorelli G. MicroRNAs and cardiac pathology. Nat. Rev. Cardiol. 6(6), 419-429 (2009).
19. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 101(25), 2981-2988 (2000).
20. van Rooij E, Sutherland LB, Liu N et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl Acad. Sci. USA 103(48), 18255-18260 (2006).
21. Cheng Y, Ji R, Yue J et al. MicroRNAs are aberrantly expressed in hypertrophic heart: Do they play a role in cardiac hypertrophy? Am. Pathol. J. 170(6), 1831-1840 (2007).
22. Sayed D, Hong C, Chen IY et al. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ. Res. 100(3), 416-424 (2007).
23. Ikeda S, He A, Kong SW et al. MicroRNA-1 negatively regulates expression of the hypertrophy-Associated calmodulin and Mef2a genes. Mol. Cell Biol. 29(8), 2193-2204 (2009).
24. Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: Functional correlates. J. Mol. Cell. Cardiol. 45(2), 185-192 (2008).
25. TatsuguchiM, Seok HY, Callis TE et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J. Mol. Cell. Cardiol. 42(6), 1137-1141 (2007).
26. Thum T, Gross C, Fiedler J et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456(7224), 980-984 (2008).
27. Lin Z, Murtaza I, Wang K et al. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc. Natl Acad. Sci. USA 106(29), 12103-12108 (2009).
28. Callis TE, Pandya K, Seok HY et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119(9), 2772-2786 (2009).
29. Bernardo BC, Gao XM, Winbanks CE et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc. Natl Acad. Sci. USA 109(43), 17615-17620 (2012).
30. Boon RA, Iekushi K, Lechner S et al. MicroRNA-34a regulates cardiac ageing and function. Nature 495(7439), 107-110 (2013).
31. Wencker D, Chandra M, Nguyen K et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J. Clin. Invest. 111(10), 1497-1504 (2003).
32. Tang Y, Zheng J, Sun Y et al. MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int. Heart J. 50(3), 377-387 (2009).
33. Chen JF, Mandel EM, Thomson JM et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38(2), 228-233 (2006).
34. Dong S, Cheng Y, Yang J et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J. Biol. Chem. 284(43), 29514-29525 (2009).
35. Qian L, Van Laake LW, Huang Y et al. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J. Exp. Med. 208(3), 549-560 (2011).
36. Nishi H, Ono K, Iwanaga Y et al. MicroRNA-15b modulates cellular ATP levels and degenerates mitochondria via Arl2 in neonatal rat cardiac myocytes. J. Biol. Chem. 285(7), 4920-4930 (2010).
37. Hullinger TG, Montgomery RL, Seto AG et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ. Res. 110(1), 71-81 (2012).
38. Rane S, He M, Sayed D et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ. Res. 104(7), 879-886 (2009).
39. Khan R, Sheppard R. Fibrosis in heart disease: Understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118(1), 10-24 (2006).
40. Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J. Mol. Cell. Cardiol. 51(4), 600-666 (2011).
41. de Jong S, van Veen TA, de Bakker JM, Vos MA, van Rijen HV Biomarkers of myocardial fibrosis. J. Cardiovasc. Pharmacol. 57(5), 522-535 (2011).
42. van Rooij E, Sutherland LB, Thatcher JE et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA 105(35), 13027-13032 (2008).
43. Wang J, Huang W, Xu R et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J. Cell. Mol. Med. 16(9), 2150-2160 (2012).
44. Duisters RF, Tijsen AJ, Schroen B et al. miR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 104(2), 170-178, 6p following 178 (2009).
45. Pan Z, Sun X, Shan H et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 126(7), 840-850 (2012).
46. Roy S, Khanna S, Hussain SR et al. MicroRNA expression in response to murine myocardial infarction: MiR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 82(1), 21-29 (2009).
47. Kumarswamy R, Volkmann I, Jazbutyte V et al. Transforming growth factor-beta-induced endothelial-To-mesenchymal transition is partly mediated by microRNA-21. Arterioscler. Thromb. Vasc. Biol. 32(2), 361-369 (2012).
48. Konstam MA, Kramer DG, Patel AR et al. Left ventricular remodeling in heart failure: Current concepts in clinical significance and assessment. JACC Cardiovasc. Imaging 4(1), 98-108 (2011).
49. Remme WJ. Pharmacological modulation of cardiovascular remodeling: A guide to heart failure therapy. Cardiovasc. Drugs Ther. 17(4), 349-360 (2003).
50. Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: A review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail. Rev. 16(1), 13-21 (2011).
51. Ai J, Zhang R, Li Y et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem. Biophys. Res. Commun. 391(1), 73-77 (2010).
52. Tijsen AJ, Creemers EE, Moerland PD et al. MiR423-5p as a circulating biomarker for heart failure. Circ. Res. 106(6), 1035-1039 (2010).
53. Ren XP, Wu J, Wang X et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 119(17), 2357-2366 (2009).
54. Hinkel R, Penzkofer D, Zuhlke S et al. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-Animal model. Circulation 128(10), 1066-1075 (2013).
55. Wang X, Zhang X, Ren XP et al. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation 122(13), 1308-1318 (2010).
56. Aurora AB, Mahmoud AI, Luo X et al. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca2+ overload and cell death. J. Clin. Invest. 122(4), 1222-1232 (2012).
57. Montgomery RL, Hullinger TG, Semus HM et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124(14), 1537-1547 (2011).
58. Care A, Catalucci D, Felicetti F et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13(5), 613-618 (2007).
59. Lagos-Quintana M, Rauhut R, Yalcin A et al. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 12(9), 735-739 (2002).
60. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: MicroRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34(Database issue), D140-D144 (2006).
61. Dash R, Kadambi V, Schmidt AG et al. Interactions between phospholamban and beta-Adrenergic drive may lead to cardiomyopathy and early mortality. Circulation 103(6), 889-896 (2001).